Thymosin Alpha-1

—

evidence score

peptide

Prescription Only

Tα1TA-1Zadaxin+2 more

Thymosin Alpha-1 (Tα1) is a naturally occurring 28-amino acid peptide derived from thymosin fraction 5 of the thymus gland. It is FDA-approved in the US as an orphan drug and approved in 35+ countries (as Zadaxin) for chronic hepatitis B and C, cancer immunotherapy adjunct, DiGeorge syndrome, and severe sepsis. It is a potent thymic hormone that matures naive T-cells, enhances NK cell activity, and restores immune competence in immunocompromised states. Growing use in biohacking/longevity communities for immune optimization, chronic infections, and post-viral syndromes (Long COVID). Extraordinarily safe profile across decades of clinical use.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Last Sync

Not synced yet

Last Reviewed

Not reviewed yet

Physician Notes

The strongest immune modulator in the peptide toolkit. Used for autoimmune conditions, chronic viral infections, and cancer adjunct therapy in 35+ countries.

FDA Status:Category 2 banned. Pending reclassification to Category 1. FDA-approved in 35+ countries (Zadaxin).

Monitoring

CBC with differential
T-cell subsets if clinically indicated

Contraindications

Immunosuppressive therapy (relative)
Organ transplant recipients

Velix Health

Want this prescribed by a board-certified physician?

Velix Health physicians review your labs, build evidence-based protocols, and monitor your progress. Every prescription is referenced.

Apply for Membership

Dosing

Typical

1.6 mg

0.8 mgRange3.2 mg

Frequency2x/week to daily depending on indication

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~2 hours

OnsetImmunological effects within days to weeks; clinical outcomes 4-12 weeks

DurationOngoing with continued dosing; effects sustained during treatment

Routes

subcutaneous_injection

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(24%)—

Quality(24%)—

Sample Size(12%)—

Consistency(14%)—

Replication(8%)—

Recency(18%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Thymosin Alpha-1 is currently categorized as a peptide compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

TLR2/9 agonism activates dendritic cells; T-cell differentiation (Th1 skew) via IL-12/IFN-γ; NK cell maturation; upregulates MHC class I expression on tumor cells

Practical Context

Strongest current signals

No indexed study summaries yet.